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Abstract
Bisphosphonates are well known class of organophosphorus compounds hav-
ing  biological  and  industrial  applications  and  their  development  is  ongoing. 
Among other   prospectives  of  bisphosphonates  the  partial  bisphosphonate  esters 
present an interest for use in biological systems with their increased lipophilicity. 
Current research is aiming to make one more step in chemistry of partial bisphos -
phonate esters with transport-optimised side chain in order to approach the calcium 
imaging utility.  The literature overview is aimed to show the dialectics of studies 
in this field and to highlight the major approaches to the synthesis of bisphosphon-
ates. The experimental part is dedicated to the problems of synthesis and purifica -
tion of individual compounds.  The synthesis and isolation of new compounds are 
described and possible reaction mechanisms are discussed.
2Abbreviations
Ala – beta-alanine
ATP- adenosine triphosphate
DIPEA – diisopropylethylamine
DMEBP – P, P'-dimethyl ethenylidene-1,1-bisphosphonate
DMF – dimethyl formamide
FPPS – farnesyl pyrophosphate synthase
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TMEBP – tetramethyl ethenylidene-1,1-bisphosphonate
TRANCE – tumor necrosis factor related activation induced cytokine
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4  1 STRUCTURE OF BISPHOSPHONATES AS A KEY BASIS FOR THEIR 
APPLICATIONS
 1.1. INTRODUCTION
Presented  thesis  is  a  part  of  larger  research  dedicated  to  bisphosphonates.  
This class of organophosphorus compounds is known over a century 1, but was ex-
tensively developed  during last  50 years owing to their  use in technological and 
medicinal aspects.  Today this field of science is still drawing interest of research-
ers and potential of this class of compounds in other fields is being discovered. The 
structure  of  bisphosphonates  determines  their physicohemical  and  biochemical 
properties.  The variation of these properties leads to variation in their behavior in  
biological systems because such systems have developed mechanisms of recogni -
tion and utilisation of xenobiotics. 
In addition to conventional  applications some new potentials  for use of bi-
sphosphonates have been proposed that require specific optimized properties and  
accordingly specific structure features. In the same time direct methods for altering  
separate  moieties  in  bisphosphonates  are  not  always  available.  Altogether this 
present  challenges for  bisphosphonate development  for  biological  and  industrial 
applications. The literature overview is intended to highlight current knowledge on 
this chemical class.
 1.2. STRUCTURAL ASPECT: TERMS AMBIGUITY AND DIVERSITY
As it  unambiguously comes  from the  name “bisphosphonates”,  these  com-
pounds  are  a  class  of  organophosphorous  compounds  bearing  two  phosphonate 
groups.  According to IUPAC recommendations  term “phosphonic acid” refers to  
structure  (HP(O)(OH)2).  Alkylphosphonic acids  are  characterized by presence  of 
alkyl  group  binded  directly  to  the  central  pentavalent  atom of  phosphorus.  The 
name for such compounds is derived from parent compound2. For instance the sub-
stitution  of  hydrogen  to  ethyl  in  phosphonic  acid  gives  ethylphosphonic  acid.  
When acidic hydrogen is substituted by carbon or by cations, it  is determined by 
word  “phosphonate”,  for  example  dimethyl  methylphosphonate  or  disodium 
methylphosphonate (Fig. 1). 
5However in common practice whole class of these compounds is historically 
called  “bisphosphonates”  regardless  of  the  substitution  of  acidic  hydrogen.  The 
term “diphosphonates” is erroneous for BPs since it describes compounds bearing 
two sequentially bonded phosphonic acid residues as it is in inorganic pyrophos-
phate (Fig. 2)3
 Whereas the name “bisphosphonate” clearly shows the presence of two phos-
phonate groups in the structure, it does not specify relative positions of these two 
functions.  Historically geminal bisphosphonates were developed most of all,  and 
omission of prefix “gem-” is common in later publications, though non-geminal bi -
sphosphonates are also studied4,5,6.  Although it is not completely correct to use the 
term “bisphosphonates” concerning only geminal bisphosphonates and/or bisphos-
phonic acids, the prefix “gem-” and ester content are omitted in this work for the 
sake of simplicity when a whole drug class is meant.
Even with restrictions mentioned above bisphosphonates present significant 
chemical  space.  Firstly  two  lateral  side  chains  on  the  central  carbon  atom may 
provide opportunity to introduce substituents of all kind involving carbon as well  
as heteroatoms.  In addition to  altering of  the side chains,  the bisphosphonic hy-
droxy groups are the points for derivation of different chemical nature (Fig. 3). 
Figure 2. Pyrophosphoric (left) and methylenebisphosphonic (right) acids.
Figure 1. The nomenclature of phosphonic acid and its derivatives.
6Ester groups or cations then can be arranged in symmetrical or asymmetrical  
fashion.  Sources  of  asymmetry are  one to  three  free  acid  hydroxyl-  and/or  non-
equivalent substituents (Table 1, general structure on Figure 3). That is why for bi-
sphosphonate with given side chain a net charge, charge distribution and sterical  
bulk  that  define  physicochemical  properties,  can  vary significantly.  For  instance 
bisphosphonic  acids  are  very  hydrophilic,  while  tetraalkyl  bisphosphonates  can  
dissolve in non-polar solvents.
Table 1. Examples of reported bisphosphonic acid esters.
Substituents Reference
R1=R4 R2=R3
Stepinski et al.7
H Octyl, cyclohexyl, Ph
Me Octyl, cyclohexyl, Ph
R1=R2=R3=R4
Cyclohexyl, Ph, 3-(Me3Si)Pr
R1=R2 R3=R4
Abdou et al.8
Et Me
H Me
Barbey et al.9R1,R2 R3=R4
Dioxalane Me
R1 R2=R3=R4
Turhanen et al.10
K+ Me
Na+ Ph
n-hexyl H
Figure 3. General structure of the geminal bisphosphonates.
7 1.3. KNOWN APPLICATIONS OF BISPHOSPHONATES
Bisphosphonates  have  four  anion centers and they can  act  as  chelator  mo-
lecules.  Chelating properties  in  case of bisphosphonates  are  expressed well  with 
divalent metal cations in aqueous media11. In a set of competitive gas phase experi-
ments divalent metal ions were substituting the host-structure of bisphosphonate.  
This model has allowed to find relative gas phase affinity values for these cations  
towards bisphosphonates used and the calcium ions have shown the highest affin -
ity12.  Reported instability constants of bisphosphonate metal complexes vary, and 
that suggests their possible use for selective chelation 13.  This property defines the 
earliest  use of bisphosphonates as agents with a broad range of industrial applica -
tions14 first of all in the metal complexing15. In spite of good achievements and in-
dustrial scale of use, the research in this field is continued revealing novel or im -
proved target properties of  this chemical class16,17,18,19.
A number of bisphosphonates are nowadays used for therapeutic purposes 20. 
Diversity of these drugs (Table 2) is due to lateral chains on the meso- atom of car-
bon while acidic functions are in free form. Within this row a division to nitrogen 
and non-nitrogen bisphosphonates  (NBPs  and NNBPs respectively)  can  be  seen. 
The domination of NBPs can be explained with early recognition of special role of  
the nitrogen in the side chain in case-by-case search of more potent structures. This  
structural  feature  becomes  more  evident  and  reasoned  as  the  mechanism of  bi -
sphosphonate action in biological systems is taken into account. 
Table 2. Bisphosphonates used in clinical therapy of osteoporosis 20 . R1 and 
R2 are substituents at the meso-atom of carbon (Figure 3).
Drug
Substituents
Potency21
R1 R2
Etidronate OH Me 1
Clodronate Cl Cl 10
Tiludronate H -CH2-S-C6H4-Cl 10
Pamidronate OH -(CH2)2NH2 102
Alendronate OH -(CH2)3NH2 102-103
Risedronate OH -CH2-3-Py 103-104
Ibandronate OH -(CH2)2N(Me)(n-C5H11) 103-104
Zolendronate OH -CH2-imidazol-1-yl >104
Neridronate OH -(CH2)5-NH2 --
Minodronate OH -CH2-imidazo[1,2-a]pyridin-3-yl --
8Currently all bisphosphonate drugs in clinical use or trial are divided to three 
generations based on combination of their structure and activity. The first genera -
tion includes NNBPs which have relatively low potency and they resemble pyro -
phosphate most of all bisphosphonates. The second generation are those of NBPs 
that  contain  amine  nitrogen substituent  and have  significant  increase  in  potency 
compared to NNBPs. Tiludronate is included in the second generation. The rest of 
bisphosphonates belong to the third generation, which is characterized by high po-
tency, heterocycle content and increased lipophilicity at the side chain terminus. 
Another utility of bisphosphonates that is widely used nowadays is imaging 22. 
The ability of coordinated bisphosphonates to preserve calcium affinity is known 23 
and that  allows such an imaging complex to  localize in  the sites  of  active  bone 
turnover. The SPECT (Single-Photon Emission Computed Tomography) is a widely 
used  technique  for  gamma-emitting  bisphosphonate  complexes.  Such  complexes 
bisphosphonates  form with  technetium-99m.  This  isotope of  technetium have an  
relatively long time of half-life (6 hours), emit gamma-radiation and transform into 
stable technetium-99 via nuclear transformation24. These complexes have shown to 
be beneficial compared to complexes of different ligands or other labels for skelet -
al imaging25,26 though different biodistribution for them is taking place 27. Altogeth-
er it makes remarkably safe, simple and reliable method for observation of dynam-
ics of the bone changes and localization of pathological processes.
 1.4. PHARMACOKINETICS OF BISPHOSPHONATES
The pharmacokinetics of bisphosphonates is a characteristic complex of prop-
erties  based on which  this  class  of  drugs  can  be distinguished from many other  
classes. These properties are summarized in several reviews 28,29,30. 
One of characteristic properties of bisphosphonates is their low oral bioavail-
ability.  This parameter can be measured by comparison of drug concentration in  
plasma after its peroral and IV administration during the time the values are above 
detectable level31. Also this parameter for bisphosphonates can be estimated by rel-
ative content of labeled drug in bone samples.  In this  way the bioavailability of  
alendronate have been estimated for test animals in range of 0.9–1,7% 32. Another 
method based on the assumption that bisphosphonate in plasma is either adsorbed 
to bone or organs or excreted with urine gave bioavailability value of pamidronate  
less than 1%27, while etidronate test in animals result in values of 2,5% the least 33. 
The extent of bisphosphanates bioavailability in plasma was also found in humans. 
9The values found according to data obtained via urine monitoring gives 0.3% for  
pamidronate, 0.7% for alendronate34, 3–7% for etidronate35 and via plasma monit-
oring  1–2%  for  clodronate36.  This  allows  rough  comparison  of  bisphosphonate 
drugs and elucidation of the drug structure role in biodistribution.
  Besides  other  available  mechanisms the  paracellular  transport  way is  re-
sponsible for bisphosphonates uptake as it is demonstrated experimentally 37,38,39. In 
theory the gastrointestinal uptake can be realised in two routes. The transcellular 
route is described as a transport  of drug through biological membranes into epi -
thelial cells from where it is distributed to other cells until it reaches blood medi -
um, but for bulk and negatively charged bisphosphonates it unlikely to take place.  
The intercellular way is formed by tight junctions of epithelial cells and is avail -
able for low-molecular compounds and electrolytes. The selective intake is defined  
by the brush-border  membrane negative charge,  electric  potential  throughout  the 
way and permeating particle size40,41. 
The physicochemical properties of bisphosphonates are crucial for the para-
cellular  transport.  These  compounds  have  molecular  weight  ranging  from  176 
g/mol for medronate to 322 g/mol for minodronate and since they are acidic they 
are in anionic form (H2L2-) at physiological pH42. The partition coefficient in octan-
ol/buffer is 0.0017 for pH range 2-1139. All in all it results in slow rates of bisphos-
phonate uptake. The additional effect comes from the divalent ions that are trans -
ported via paracellular transport and that hinder passing the tight junction by large  
anionic  molecules.  This  is  supported  by  dose-dependent  studies  with  additional 
complexing agents  in  vitro43,44 and  in  vivo45.  In  accordance with this  the cations 
hinder  the  tight  junctions  passages  and their  removal  by chelation  improves  the 
drug transport.
Once the bisphosphonate is in plasma it is rapidly absorbed by the skeleton, 
by kidney and to a small degree by other tissues (Figure 4). This distribution is af -
fected by bone affinity of the drug, rate of bone turnover and renal function 29. The 
bisphosphonate which is absorbed by non-calcified tissues is rapidly decaying and 
removed by urinary excretion. Scaling up of the dose results in larger bisphosphon-
ate deposition and longer release, while distribution of the drug is the same 46,47. 
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 1.5. BISPHOSPHONATES AS DRUGS FOR BONE DISEASES
Bisphosphonates have been known for over a century1, but their relevancy to 
the  calcium homeostasis was shown only about 50 years ago 48. Today this class of 
drug is a treatment of choice for patients with bone resorption diseases and Paget's  
disease. This chapter is intended to show the evolution of views on bisphosphonate  
action on bone homeostasis. The main target organ for this action is the bone and  
brief highlight of this topic appears to be essential for understanding of bone-re -
lated processes. 
The living bone is a porous structure of  fluid, living cells and mineral that is  
closely related to hydroxyapatite. In normal healthy organism the bone undergoes  
continuous  renewal  process49. The  bone  remodeling  function  is  executed  on  the 
cellular  level  by iterative removal  and the formation of the mineral on available 
bone surfaces. Osteoclasts and osteoblasts are two different lineages of cells that 
are  responsible  for  mineral  removal  and  regeneration  respectively 50.  Osteoblasts 
are  recruited from mesenchymal  (or stromal)  stem cells  and they mainly form a 
mineralisation matrix51 and regulate osteoclast  activity52. Osteoclasts are of leuco-
cyte-related origin and they mobilize  the bone mineral and the matrix. The mineral  
resorption  occurs  via  acidification  of  individual  osteoclast  site53. The  bone cells 
form aggregates – so-called bone remodeling units – in which osteoclasts  are on  
the moving frontier and the osteoblasts are following osteoclasts in formed depres -
sions. Remodeling process is normally in an equilibrium state unless it is shifted  
by some system or  local  factors54.   The  lack  of  knowledge about  physiology of 
bone on the cellular level is explained by difficulties of observing living bone  in  
vivo. 
Figure 4. A simplified model of  bisphosphonates ADME. A – absorption, D – diges-
tion, M – metabolism, B-HAP – biogenic hydroxyapatite, E – excretion.
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The history of bisphosphonates studies in biological field began in late 1960s 
from the studies of Herbert Fleisch pioneer team. In 1966 they demonstrated that  
urine and plasma components have inhibitory effect in vitro on calcium phosphate 
precipitation.  An  inorganic  pyrophosphate  was  recognized  as  one  of  the  natural  
factors  responsible  for  calcium  homeostasis. In  vivo this  compound  has  shown 
such an effect on ectopic sites of calcification but no effect was observed on the 
other sites of calcium phosphate turnover55. This fact was explained by lability of 
pyrophosphate  to  phosphatase  degradation  and  led  to  experiments  with  already 
known structural  analogs  –  bisphosphonates.  Bisphosphonates  with  their  P–C–P 
backbone have proved to be stable in aqueous media by then in industry 15. Follow-
ing the expectations, in vivo these compounds have been stable against phosphata-
se as well48,56.  According with the major application of bisphosphonates in  more 
common osteoporosis treatment literature overview will highlight bisphosphonates 
in cases of bone resorption. Nevertheless the pathologic mineralization phenomena 
such as Paget's disease, ossification or urinary stones cases give additional oppor-
tunity to demonstrate an effect of bisphosphonates on the mineral balance of the  
body.
The mode of bisphosphonate action on calcium deposition/resorption was re-
considered as studies on this class of drugs were becoming more sophisticated. The  
data from different stages of study clearly reflect different, sometimes controver -
sial views on the subject. As of 2011 after long and extensive research it appears to  
be clear what are the ways the bisphosphonates affect bone resorption and integer 
image can be made57. As a consequence of this general assumptions may be done 
to  systematically  overview  major  interactions  of  bisphosphonates  at  resorption 
sites. In simplified model a complex  role of bisphosphonates can be represented as 
independent interactions on the cellular or molecular level (Figure 4). 
1.5.1. HYDROXYAPATITE AS A MODEL FOR BISPHOSPHONATE-BONE INTERACTIONS
The molecular level of bisphosphonates action (A, Figure 4) was the first to 
be  proposed.  In  straightforward  approximation  the  mineral  resorption  inhibition 
can be explained by chelating properties of bisphosphonate molecules. There are 
studies that confirm that hydroxyapatite surface stability is strongly dependent on  
the surrounding medium58. However a contribution of bisphosphonates to the min-
eral resorption via solution effects (i.e. without binding to the mineral surface) is  
not reported if extreme dosages are not taken into an account 59 This is consistent 
with  major  effect  attributed  to  bisphosphonates  in  industrial  applications  as  de -
scribed in previous chapter. 
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On the other hand  bisphosphonates immediately bind to a mineral surface. 
Possible  effects  are  more  evident.  Here  two  hypotheses  of  binding  can  be  pro-
posed.  Firstly it can be a formation of  layer of bisphosphonate that isolate outer  
media  from  the  mineral.  Secondly  an  incorporation  of  bisphosphonate  into  the 
mineral will  provide an increased stability against hydrolysis of the formed non-
homogenic structure. The surface binding and structural incorporation are not ne -
cessarily exclusive processes. A layer of chelating molecules can be theoretically  
included in the mineral structure provided such layer will have a low density al -
lowing  mineral  components  to  precipitate.  These  hypotheses,  although  not  con -
firmed directly, are consistent with experimental results. For instance it is shown 
that bisphosphonates form a continuous layer on the surface of hydroxyapatite as a  
crystal-growth poison60 As for incorporation in solid structure it was observed for 
alendronate in vivo61. It is possible to state at the current state of study that regard-
less on the exact mode of binding of bisphosphonates they are accumulated in the  
bone. 
The biodistribution of bisphosphonates is such that bone tissues are exposed 
to these compounds in high degree28. Theoretical studies show a basis of binding of 
these  compounds  to  hydroxy apatite  depending on the  binding  surface62 and the 
chelating  structure63.   Bisphosphonates  are  believed to  be bidentate  or  tridentate 
chelating molecules depending on the α-hydroxyl functionality64,65,66.
According to mentioned effects bisphosphonates,  regardless to the mechan-
ism the bone resorption is inhibited, primarily bind to the surface of the bone. The  
hydroxyapatite  bone affinity therefore  determines  the  accumulation  of  the  given  
structure in target tissue and can be used to pre-evaluate the drug candidate67,68,69. 
Figure 4. Bisphosphonates and a bone resorption. Abbreviations: BPs - bisphosphon-
ates, BHA - biogenic hydroxyapatite, SI - solvated ions, Oc - steoclasts, Ob - osteo-
blasts, OcG - osteoclastogenesis.
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Consequently related parameter of the bisphosphonate release makes possible pre -
diction of pharmacokinetics of these drugs.
First discoveries have revealed that bisphosphonates can inhibit ectopic min-
eralisation and suppress the bone resorption in vivo and it was consistent with early 
views on factors of these compounds action. However attempt to find a relation-
ship of bisphosphonates resorption inhibition in vivo and  in vitro on the one hand 
and purely physicochemical prevention of hydroxyapatite resorption on another did  
not give clear  result. It was suggested that bisphosphonates have a cellular mech-
anism of action70.
To conclude hydroxyapatite gives an insight to the properties of the bone and 
the  bisphosphonates.  Hydroxyapatite  gives  possibility  to  pre-evaluate  new  drug 
candidates  that  are  targeting  bone.  But  as  any model  hydroxyapatite  has limita-
tions. The differences of the bone and inorganic hydroxyapatite structure are so far  
not brought up and the observation of cellular effects requires more complex mod-
els.
1.5.2. DO BISPHOSPHONATE CYTOTOXIC AND ANTI-RESORPTION EFFECTS 
CORRELATE?
Cellular nature of bone remodeling suggests interference of bisphosphonates 
with specialized cells (B, C Figure 4.). Early basis for this idea was a study demon -
strating the ability of bisphosphonates to affect rodent calvaria cells cytotoxically 
in vitro and in vivo70.  Good correlation was found also between cytotoxic and anti-
resorbing action of bisphosphonates as an indication of the role of cytotoxic effect 
in target property71. The latter of mentioned experiments have been set with amoe-
bae  Dictyostelium discoideum  thus cytotoxic effect of bisphosphonates is not ex-
ceptional for bone cells though in vivo in mammals their selective action might be 
determined by their biodistribution. 
The concept of cytotoxic effect of bisphosphonates can explain inhibition of 
bone resorption whether the target was only osteoclastic or both types of bone cells  
(B, C, Figure 4.). In theory the induction of bone cells apoptosis as such should af -
fect bone cells equally. However a real selectivity for cytotoxic effect is influenced 
by drug localisation. Osteoclasts have been shown to release bisphosphonate from 
bone during acidification61. This suggests that bisphosphonates are affecting osteo-
clast cells in the resorption lacuna and an exceptionally high exposure to the drug 
takes place.  In full  consistence with this the observation by Coxon  et al72.  show 
that osteoclasts are affected by major part of bisphosphonate during bone dissolu -
tion while non-resorbing cells receive minor part of the compound.
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The direct introduction of bisphosphonates into the bone macrophages from 
solution most likely takes place like in case of Caco-2 cells 73,74. In the same time it 
is known that the concentration of these drugs in biological media outside of re -
sorption site is low. Thus action via biological media on the cellular targets espe-
cially those of the osteoblasts  should be highly specific to have an effect. 
Biochemical targets of bisphosphonates in conditions when they induce apop-
tosis are known to a representative degree. Here the division to NBPs and NNBPs 
becomes justified when diverse effects of these subclasses of bisphosphonates are  
observed. Possibly the first evidence in this question was obtained in 1988 when 
Klein  et al. found that medronate (methylene-1,1-bisphosphonic acid) is metabol -
ised  into  analogues  of  adenosine  triphosphate  (ATP)75. Studies  of  Rogers  et  al. 
have shown that other NNBPs  (etidronate, clodronate) are also metabolized into  
analogues of ATP76,77. These biogenic analogues mimicking regular ATP are known 
to be enzymatically stable78.  This fact together with essential  role of ATP in cell 
metabolism can explain the cytotoxic effect of these NNBPs 79. NNBP tiludronate is 
reported  to  have  specific  effect  on  osteoclast  ATP-ase  in  acidification  volume 
though  the  fact  of  incorporation  of  tiludronate  into  ATP analogues  remains  un -
clear26. 
Molecular  targets  of  NBPs are also known. The involvement  of NBPs in a 
protein  isoprenylation  part  of  mevalonate  pathway  was  demonstrated  in  several 
studies81,82.  This  pathway  has  been  shown  earlier  to  utilize  pyrophosphate  sub -
strates83. The  farnesyl pyrophosphate synthase (FPPS) has been identified as the 
main target of bisphosphonic ligands. This enzyme is a key part of the mevalonate 
pathway that  is  essential  for  protein  isoprenylation.  The  GTPases  which  are  in -
volved in many cellular functions are isoprenylated along this pathway. Therefore  
the blocking of GTPases isoprenylation leads in extreme case to apoptosis of os -
teoclast.  The downstream enzyme geranylgeranyl  pyrophosphate synthase is  also 
reported to be inhibited by bisphosphonates though to a lesser degree 84. The recog-
nition of  FPPS and more generally mevalonate pathway as  anti-resorption target 
led to a simple models. Available stamms of  Dictyostelium discoideum and more 
specific human FPPS proved to be efficient. The order of potency of NBP against  
FPPS corresponds to that of anti-resorbtion (Table 3).
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Table 3. The comparative list of bisphosphonate drugs activity.
Bisphosphonate drug
IC50 (nM), human 
recombinant FPPS85
Potency relative 
to etidronate21
Pamidronate 200 102
Alendronate 50 102-103
Ibandrobate 20 103-104
Risendronate 10 103-104
Zolendronate 3 >104
The concept of apoptosis of  the osteoclasts  as a mode of bisphosphonates  
action is reasoned and well described. In practice the inhibition of bone resorption 
can happen without osteoclast apoptosis. Such results were derived from the exper -
iment  involving  NBPs  as  well  as  NNBPs  in  dose-response  studies.  It  has  been 
shown that  whereas NNBPs affect  osteoclast  functions mainly through apoptosis 
induction, NBPs are able to exhibit the target property without inducing apoptosis 86 
. Moreover in certain observations bisphosphonates have been shown to prevent ar -
tificially induced apoptosis87. Answering the heading question osteoclast apoptosis 
leads to reduction of bone resorption as it happens in case of NNBPs and NBPs in  
higher doses, but this is not a necessary condition for a target effect on the bone re -
sorption.
1.5.3. OSTEOBLAST RELATED ACTION OF BISPHOSPHONATES 
There are evidences that osteoblasts regulate the resorption activity of osteo-
clasts  by a  signalling  system-osteoprotogerin88 which is  identified  also  as  a  cell 
survival factor89. This signalling factor was identified in different studies as an os-
teoprotogerin (OPG), RANK (receptor activator of nuclear factor-κB)90, TRANCE 
(tumor  necrosis  factor  (TNF)  related  activation  induced  cytokine)91.  Along  with 
this factor there is a corresponding ligand factor (OPGL) that is involved in differ -
ent regulation patterns. Besides all this factor mediates osteoclasts' differentiation 
and activity92.  The ligand and OPG factor  bind to each other  and the balance of 
OPG and OPGL define how much the osteoclast promotion signal is expressed (C,  
Figure 4). In such a way the regulation of osteoclasts activity is supposed to hap -
pen normally93.  NBPs have been found to affect this mechanism by inducing the 
expression of OPG88,94. The increase in OPG expression consequently might lead to 
reduction of bone resorption and an increase in cell survival. 
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The  pharmacophore  of  bisphosphonates  can  be  virtually  divided  to  P–C–P 
moiety (where P stands for phosphonate group) which is strongly limited in modi -
fication and side chains where the variations are more possible. The bone affinity  
and FPPS (and to a less extent GGPPS) inhibition both should be expressed in a 
potent structure for increase of bone resorption inhibition. The P–C–P part is es -
sential for binding to the bone mineral since its geometry is optimal for binding to 
calcium and this  property is  described above. Addition of the hydroxyl  group in 
gem position to phosphonic groups increases bone affinity as well 95. As for the side 
chain of more potent NBPs it also has a positive effect in bone binding due to nuc -
leophilic  nitrogen63.  The interaction of bisphosphonates with FPPS is  defined by 
successful resembling of dimethylallyl pyrophosphate substrate (Figure 5.). From 
the crystal structures of protein-ligand complex it can be seen that side chain be-
sides  nitrogen   region  also  has  a  lipophilic  region  that  is  responsible  for  di-
methylallyl chain mimicking96. This also can be concluded from equal activities of 
zolendronate and more lipophilic minodronate85.
To conclude the chapter bisphosphonates have a diverse mode of action de-
pending on their structure, dose and cells involved. From the recent reviews it ap-
pears that there is a consensus on what mode of action for NBPs and NNBPs con-
tribute more or less to resorption inhibition97,57. Bisphosphonates are binding to the 
bone surface and are released during osteolysis. NNBPs are metabolised to relat -
ively inert ATP-analogues and thus exhibit cytotoxic action reducing the number of  
resorption sites. NBPs inhibit farnesyl pyrophosphate synthase reducing the activ -
ity of osteoclasts in extreme case inducing their apoptosis.
 1.6. BISPHOSPHONATES: NEW CONCEPTS
The  pharmacokinetical/pharmacodynamical  profile  of  bisphosphonates  is 
rather specific. Generally bisphosphonic acids are poorly absorbed in gastro-intest -
inal tract, then rapidly distibuted in plasma so that with minor exceptions one part  
binds to the skeleton and another is excreted by kidneys. The bisphosphonate that  
is binded to the bone is then released during normal or pathological bone resorp-
Figure 5. Dimethylallyl pyrophosphate - a natural FPPS ligand
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tion. Depending on the structure of the released compound it is either metabolised 
to ATP analogue or it interact with enzymes of protein isoprenylation, mainly with 
FPPS. The more detailed description of the mentioned subjects is available in two 
previous sections.
  Along the way described above there are limitations on the way of bisphos-
phonic compounds. Firstly, the molecular weight and explicit negative charge limit  
the uptake and paracellular transport of these compounds, reducing their amount in  
plasma. Secondly, the bone affinity determines the extent of bisphosphonate bone 
sorption.  Bisphosphonates  are  typically  not  reaching  high  concentrations  in  soft 
tissues excluding kidney29,46,47.   In the same time bisphosphonates posses several 
properties that can be of use in parts of the body that are distant from the skeleton 
or  renal  function. For  instance,  bisphosphonates  have  a known  potency  against 
both bone related and unrelated tumor processes98,99,100. The activity against proto-
zoan parasites  Trypanosoma cruzi and  Toxoplasma gondii  that act  in internal  or-
gans is also  evaluated101,102,103. These directions of bisphosphonate activity on the 
first  place  and bone-related  utilities  (e.g.  Paget's  disease  and osteoporosis  treat -
ment, skeletal imaging) suffer severe drawback from poor availability of bisphos -
phonates in plasma and more specifically in bone-distant tissues. 
Since every significantly active xenobiotic compound expresses its  potency 
against  its  target  in  micro-  and nanomolar  range  the  bioavailability  is  a  crucial  
factor of improving overall potency of the drug. A prodrug is a derivative of known 
biologically active compound with improved absorption and digestion that is meta -
bolised into an active drug in proximity to its biological target. There is a constant  
interest  to  the  improvement  absorption,  digestion,  metabolism  and  excretion 
(ADME) properties of drugs so that a prodrug methodology is developed as well. 
A prodrug concept has been applied to various drugs with aspirin being the classic -
al  example  and  since  then  the  modification  techniques  became  more  sophistic-
ated104. 
In  case  of  bisphosphonate  drugs  a  successful  prodrug strategy for  the  side 
chain of NBPs resulting in better oral absorption is known 105,106. In the same time 
for potent compounds, when the side chain is a determinant of a target properties  
varying this region might mean a high price in inhibition as such. Another point 
against varying of the bisphosphonate lateral chains is  possibility the conjugation 
of this bone targeting scaffold with other biologically active compounds in order to  
reach selective effect of latter. The concept of bone-targeting bisphosphonate con-
jugation is continuously studied107,108,105 and general image of the subject is made in 
reviews109,110.
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On the other hand the phosphonate groups play a major role in physicochem-
ical properties of compounds in question and their modification appears to be most 
efficient in respect to the balance of target specific and transport optimised proper -
ties.  An  acid  charge  masking  by  esterification  is  a  well  known  method  within  
phosphate type prodrug approaches111. This simple method allows biologically act-
ive phosphorous compounds to reach higher drug efficacy though with lesser effect 
that  with  more  complicated  kinds  of  masking112. In  case  of  bisphosphonates  the 
charge masking is expected to improve membrane permeation as well 113. There is 
an optimal number of the ester groups since tetraester bisphosphonate will have a 
poor water solubility.  Technetium-99m imaging in organs require relatively lipo -
philic complexes as shown with various ligands114,  thus for imaging purposes an 
optimum between complexing and drug-like properties should be found. Techne -
tium-99m might also contribute to decrease of anionic character of bisphosphon -
ate115 and the results of recent study suggest that symmetrical bisphosphonate di-
esters have reduced bone affinity compared to free bisphosphonic acids 116.  How-
ever, the persistence of such compounds in plasma is yet to be evaluated.
To conclude a  symmetrical  masking of  two hydroxyl  groups  in  a  bisphos-
phonate appears to be a reasoned compromise between all the range of properties 
of the bisphosphonate class. This method, once developed, might bring a benefit in 
bioavailability with remaining variety of potential  uses and could be a  universal  
tool for development of this class of compounds. 
 1.7. SYNTHETIC APPROACHES TO BISPHOSPHONATES
The first synthesis of bisphosphonates dates back to 1865117. A simple deduc-
tion of the P–C–P backbone suggests two main approaches to bisphosphonates as a 
class. The first one is an assembly of P–C–P backbone from separate reactive spe-
Figure 6. Bisphosphonate structure optimisation
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cies allowing the carbon part to bear some useful moiety (A,  Scheme 1). Another 
one divides the P–C–P backbone and the side chain formation (B, Scheme 1) 
 1.7.1. SYNTHESES INVOLVING  P–C–P BACKBONE ASSEMBLY
The classical approach via Michaelis-Arbusov reaction is based on the reac-
tion of halogenated substrate (1, Scheme 2) with trialkylphosphite and subsequent 
reaction of formed phosphonate (2) with reactive dialkyl phosphonate. For instance 
Binderup118 has described such a method of synthesis from a dihalogenated starting 
material.  Interestingly,  a  target  bisphosphonate (3)  can  be obtained by treatment 
with each of individual phosphonating agents alone, though dialkyl phosphonates  
lead to a lesser yield of 3.   
A reactive starting material for introduction of the second phosphonate group 
can  be  prepared  by  α-halogenation119.  After  this the  phosphonation  proceeds 
smoothly (Scheme 3).
Scheme 2
Scheme 1. Two types of approach to bisphosphonates
20
The sharing of  α-position by fluorine and easy leaving halogen (7,  Scheme 
4.)  results  in cleavage of latter  during the reaction allowing a synthesis  of more 
lipophilic  P–C–P part  (9)120.  In the same time using perhalogenmethane CF2Hal2 
results in lesser yield and significant side reactions120.
As shown by Abdou et al.8 a pseudohalogen group exhibits analogous react-
ivity and can be utilized for second stage phosphonation (Scheme 5). That particu-
lar study have shown an approach to asymmetrical bisphosphonates.
When a target product requires a presence of nitrogen and trifluoromethyl on 
the meso-atom of bisphosphonate (16, Scheme 6) the trifluoro-acetimidoyl chloride 
(13) can be used121,122,123.  The phosphonation itself  occurs without halogen cleav-
age.
Scheme 3
Scheme 4
Scheme 5
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An  α-nitrogen  functionality is  also provided by reaction of  amine with tri-
ethyl-orthoformate and phosphonating agent in one pot synthesis 122 (Scheme 7). A 
further highlight of aminobisphosphonates synthesis is provided by the review by 
Romanenko et al124.
A diethyl phosphorochloridite have proved to be an efficient phosphonating 
agent in reactions with linear and alicyclic carbonyl substrates 125 (Scheme 8).
Scheme 7
Scheme 6
Scheme 8
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Other carbonyl substrates can be used for bisphosphonate design as well. For 
instance carboxylic acids were treated with phosphorus trichloride and then intro -
duced in reaction with trialkyl phosphinite and dialkyl phosphonate yielding 1-hy-
droxy-methylene-1,1-bisphosphonate  (27)  with  pre-defined  side  chain11 (Scheme 
9).
An interesting approach is provided by use of dimethyl formamide acetal ma-
terial  (28).  The  reaction  with  phosphonating  agent  is  going stepwise  allowing a 
synthesis of asymmetrical bisphosphonates (30)126 (Scheme 10).
 1.7.2. SYNTHESES UTILISING READY  P–C–P BACKBONE
The  synthesis  starting  from methylene-1,1-bisphosphonate  starting  material 
(31, 32)  is  widely used.  The hydrogen atom in  meso-position of bisphosphonate 
structure shows acidic properties and under metal hydride treatment leads to form-
ation of reactive anion. This property is utilised in reactions with halogenated sub -
strates127,128 (Scheme 11) and with activated π-systems129 (Scheme 12).
Scheme 9
Scheme 10
Scheme 11
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Method  based  on Michael  addition  of  ethenylene-1,1-bisphosphonates  (41-
43) allows  synthesis  of ethylidene-1,1-bisphosphonates  (44-64).  The reports  re-
garding the Michael addition  of methylene-1,1-bisphosphonates differ in bisphos-
phonate  protection  and attacking nucleophile  (Scheme 13).  Methyl-,  ethyl-,  or  a 
trimethylsilyl- protective groups are removed after the target structure is obtained. 
Nucleophile may be oxygen, sulfur, and more commonly nitrogen.  The diversity of 
bisphosphonate Michael additions is expressed in Tables 4 and 5. Based on repor-
ted results it can be proposed that important  factors are nucleophilicity of the at -
tacking molecule, protection of phosphonate groups and protection-dependent re -
action media. 
Table 4.
N Nucleophile
Protection 
group, R
 Yield, % Reference
44 H2O
Et
87 Bailly et al.130
45 HS-Ph
90
Hutchinson et  
al.131
46 HS-Et
47 HS-Pr
48 H2N-(CH2)4-NH2 93
Szajnman et  
al.101
49 H2N-Bu 92
50 H2N-iPr 79
51 H2N-tBu 71
52 Cyclohexylamine 66
Scheme 12
Scheme 13
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Table 5. 
N Nucleophile Protection 
group, R
 Yield (acid form), % Reference
53 Cyclopropylamine
Me3Si
93
Schevchuk et  
al.116
54 H2N-tBu 99
55 Cyclohexylamine 99
56 3-amino-pyridine 75
57 2-aminopyridine 75
58 H2N-Me
OH
94
Alfer'ev et al.117
59 H2N-Et 71
60 H2N-C(CH2OH)3 49
61 HNEt2 85
62 Piperidine 95
63 Glycine 100
64 β-alanine 95
 1.7.3. METHODS OF ALTERING THE BISPHOSPHONATE PROTECTION 
Various forms of bisphosphonic acid esters are reported (Table 1). Possibly 
the main reason for well described bisphosphonate acid esters chemistry is that the  
starting materials for the synthesis of bisphosphonate structure as such are phos -
phites and  phosphonate acid esters. Once the  P–C–P backbone and laterial chains 
are formed the protection groups are removed by one of methods.
Generally the simplest  from synthesis point of view are full homoleptic bi -
sphosphonate esters and bisphosphonic acids since former do not require additional  
transformations  after  the  P–C–P backbone  is  ready and  latter  are  obtained  with 
simple procedures. The typical method in literature is an acid hydrolysis, 132,8,101 and 
more mild method utilising bromotrimethylsilane exists as well131,133(Scheme 14).
Scheme 14
25
The bisphosphonate tetraester have been shown to form from bisphosphonic 
acid upon treatment with orthoformate134 and from bishosphonic acid chloroanhyd-
ride  upon  treatment  with  alcohol135.  However  an  isolation  of  partial  esters  as  a 
semi-products  of  total  esterification  or  hydrolysis  appears  to  be  sub-optimal 
way135.
An interesting approach to partial (69), homoleptic (31, 32) and mixed (70) 
symmetrical bisphosphonate esters was demonstrated by Stepinski et al.7. With tet-
razole catalysis,  a stochiometrically controlled136 reaction takes place and two or 
four ester groups can be introduced to bisphosphonate scaffold (Scheme 15).
Partial  bisphosphonate  esters  can  be  formed  from fully  protected  bisphos-
phonates by treatment with selective reagents. This way provides a choice of pro -
tection positions to be cleaved than hydrolysis method does. For instance in series  
of studies135,137,10 it has been shown that depending on the target esterification and a  
starting bisphosphonate ester a specific method can be applied. 
For stepwise removal of ester groups in asymmetrical fashion a stochiomet-
rically  controlled  treatment  by  trimethylsilylcloride  and  sodium  iodide  in  basic  
methanol can be chosen135 (Scheme 16). 
The application of amines results in selective cleavage of ester groups 137: one 
group  upon  treatment  with  tertiary  or  aromatic  amine  (77,  Scheme  17)  or  two 
Scheme 15
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groups  upon treatment  with  secondary amine  (75).  If  more  harsh  conditions  are 
provided a treatment by pyridine gives a P,P'-dialkylbisphosphonate (78,  Scheme 
18) while treatment with morpholine gives bisphosphonate monoesters (80). 
Besides trimethylsilylhalogens and amines the metal halogen salts act as a se -
lective deprotection agents. In mild conditions sodium iodide has been found to be  
selective methyl cleavage reagent and use of lithium chloride results in more gen-
eral deprotection10(Scheme 19). 
Scheme 16
Scheme 17
Scheme 18
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The methods shown above reflect an approach utilizing a ready P–C–P backbone.  
However a synthesis of bisphosphonates with pre-defined protection is also pos -
sible.  A set  of protection groups in  P,P'-dialkylbisphosphonates  (92,  Scheme 20) 
have been achieved with use of bis(trimethylsilyl)alkylphosphite (91) in four step 
method138. 
Scheme 20
Scheme 19
28
The  synthesis  of  asymmetrical  bisphosphonate  diesters  becomes  possible 
with application of different monophosphorous species for the Michaelis-Arbuzov 
reaction.  In this  methodology trimethylphosphate and 4,4,5,5-tetramethyl-[1,2,3]-
dioxaphospholane 2-oxide form bisphosphonate tetraester with two differently pro-
tected hydrolytically labile groups (94) 9 (Scheme 21).
A stepwise  method  developed  by  Abdou  et  al.  involves  Horner-Wittig re-
agents8 (Scheme 22). 
The methods shown above form a basis for synthesis of various bisphosphon-
ate esters on diverse stages and from diverse starting points. The choice of particu -
lar method therefore should be consistent with a synthetic strategy for a given tar -
get bisphosphonate. 
 1.8. THE AIM OF THE RESEARCH
The literature review shows that bisphosphonates in biological applications 
were  developed  mainly  in  bone  selectivity  and/or  specific  enzymes  inhibition, 
whereas lesser attention was made for improvement of their ADME properties. 
The current study is aimed to the synthesis of methylene-1,1-bisphosphonates 
diesters bearing a conjugation function in lateral  chain as universal mean for bi -
sphosphonate development and for transport purposes. 
Scheme 21
Scheme 22
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  2 EXPERIMENTAL PART
2.1. METHODS AND MATERIALS
2.1.1. GENERAL
The basic method for reaction observation and compound analysis was 1H, 31P 
and 13C NMR spectroscopy. TLC was used for purity evaluation when it was pos-
sible.  The  NMR  was  acquired  using  Bruker  Avance  500  DRX  instrument with 
working frequency of 500.13 Hz, 202.46 Hz and 125.77 Hz for 1H, 31P and 13C nuc-
lei respectively.  The 31P and  13C NMR spectra were acquired in proton decoupled 
mode. Spectra were routinely obtained in deuterium oxide at neutral pH if other is 
not specified with referencing of the signals to  sodium 3-(trimethylsilyl)-1-propan-
esulfonate  (TSP, 0 ppm).  The  coupling constants are  reported in  Hz. The related 
coupling constants are reported if the difference in values does not exceed 0.1 Hz.
2.1.2. MATERIALS
Solvents used in reactions were used as supplied. When required dry solvents 
were prepared by distillation over drying agents and used under dry argon medium. 
Tetramethyl-methylenebisphosphonate  (98%) was  supplied  by ABCR,  Karlsruhe, 
Germany and used as is. Tetramethyl-ethenylidene-1,1-bisphosphonate and P,P'-Di-
methyl-ethenylidene-1,1-bisphosphonate were prepared according to the literature 
methods of  Degenhardt et al.123  and Turhanen et al.10 respectively; the purity not 
less than 90 %  estimated by NMR. 6-Aminocaproic acid (99+%) was supplied by 
Acros  Organics,  beta-alanine  (98%),  gamma-aminobutyric  acid  (97%)  were sup-
plied  by Aldrich  and  L-lysine(98%  monohydrate)  was  supplied  by Sigma.  Free 
aminoacids  were  mostly  used,  but  for  experiments  with  protected  aminoacids 
methyl esters of beta-alanine, gamma-aminobutyric and 6-aminocaproic acids were 
synthesized by facile  method139  using trimethylsilyl  bromide (97 %, Aldrich) or 
trimethylsilyl  chloride  (99  %,  Aldrich).  For  reactions  in  DMF  pyridinium  di -
chlorozincate complex (1M solution in DMF, prepared and stored separately in dry 
conditions) was used in order to dissolve free aminoacids 140. Silica gel 60 (Merck) 
was  used  for  routine  column  chromatography.  Strong  acid   Amberlyst  15  and 
strong base Dowex  1x8 resins  were implied for  ion exchange experiments.  TLC 
plates  were  Merck silica  gel  60  F254  and  neutral aluminium oxide  60  F254  de-
veloped with iodine or observed with 366nm UV irradiation.
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2.1.3. PREPARED COMPOUNDS
A summary of transformations performed in the study is shown in the Scheme 23.
Tetramethyl ethenylidene-1,1-bisphosphonate (99, TMEBP)
Paraformaldehyde (3.90 g, 129.9 mmol) and diethylamine (1.88 g, 25.7 mmol) were 
dissolved in 50 ml of dry methanol with heating under dry argon. Clear solution was 
cooled down and tetramethyl methylenebisphosphonate (6.00 g, 25.8 mmol) in 10 ml of 
dry methanol was added. The mixture was refluxed for 2 hours and the solvent was 
evaporated. Then 10 ml of dry toluene was added and the mixture was concentrated un-
til complete removal of solvent. The latter procedure was repeated to ensure removal of 
all methanol. Then 50 ml of toluene and catalytic amount of p-toluenesulfonic acid were 
Scheme 23. I –  Degenhardt et al.142; II –  Turhanen et al.10, III – present study 
IV – Houghton et al.147, V – Li, Sha139, VI – Ryadnov et al140.
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added and the mixture was refluxed with Dean-Stark trap overnight. The resulting mix-
ture was distilled  under  reduced pressure (121-137 °C/2.9-1.2 mbar)  yielding 4.63g 
(72.4 %, purity est.  90%).  1H NMR (CDCl3):  7.03 (2H, m,  =CH2);  3.80 (12H, m, 
OCH3);  31P NMR (CDCl3): 16.7 (s); 13C NMR (CDCl3): 150.6 (s, =CH2); 130.4 (t, 1JCP = 
167.6, PCP); 53.5 (t, 3JCP = 2.89, OCH3);  
P,P'-dimethyl ethenylidene-1,1-bisphosphonic acid (100, DMEBP)
Tetramethyl ethenylidene-1,1-bisphosphonate (2, 0.500 g, 2.07 mmol) was dissolved in 
3 ml of acetone, then sodium iodide (0.609 g, 4.15 mmol) was added. The mixture was 
refluxed for 3 hours and then formed precipitate was filtered, washed with acetone and 
dried in vacuum until constant weight. Yield 0.295 g (55.3 %) 1H NMR: 3.53 (6H, m, 
OCH3); 6.55 (2H, m, =CH2). 31P NMR: 14.5 (s). 13C NMR: 142.42 (s, CH2); 52.46 (s, 
OCH3).
General procedures for synthesis of protected aminoacids139
Trimethylsilyl chloride or bromide(2 equiv.) was slowly added to dry aminoacid (1 
equiv.) in flask with stirring. Contact of reaction mixture with metal and air moisture 
was avoided. When the mixture became clear an excess of methanol was added. A pre-
cipitate of protected aminoacid was filtered, washed with acetone until visibly clean and 
dried in vacuum until constant weight.
Βeta-alanine methyl ester hydrochloride (109)
Trimethylsilyl chloride (2.173 g, 20 mmol) was slowly added to β-alanine (0.891 g, 10 
mmol) and stirred until clear solution was formed. Then 10 ml of methanol was added, 
precipitate was filtered, washed with 20 ml of acetone and dried in vacuum until con-
stant weight. Yield 0.859 g (61.6 %) 1H NMR: 3.69 (3H, s, -CO2-CH3); 3.24 (2H, m, 
-CH2-CO2-); 2.77 (2H, m, -CH2-NH2).
Gamma-amino butyric acid methyl ester hydrobromide (110)
Trimethylsilyl bromide (97 %, 3.1567 g, 20 mmol) was slowly added to γ-aminobutyric 
acid (1.012 g, 10 mmol) and stirred until clear solution was formed. Then 10 ml of 
methanol was added, precipitate was filtered, washed with 20 ml of acetone and dried in 
vacuum until constant weight. Yield 0.525 g (26.5 %) 1H NMR: 3.72 (3H, s, -CO2-CH3); 
3.05 (2H, m, -CH2-CO2-);  2.54 (2H, m, -CH2-NH2); 1.97 (2H, m, CH2).
6-Aminocaproic acid methyl ester hydrobromide (111)
Trimethylsilyl bromide (97 %, 3.1567 g, 20 mmol) was slowly added to 6-aminocaproic 
acid (1.3117 g, 10 mmol) and stirred until clear solution was formed. Then 10 ml of 
methanol was added, precipitate was filtered, washed with 20 ml of acetone and dried in 
vacuum until constant weight. Yield 0.629 g (27.8 %) 1H NMR: 3.70 (3H, s, -CO2-CH3); 
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3.00 (2H, m, -CH2-CO2-); 2.43 (2H, m, -CH2-NH2); 1.67 (4H, m, -CH2-CH2-CH2-); 1.41 
(2H, m, -CH2-CH2-CH2-).
Pyridinium dichlorozincate (113)140
Dry zinc chloride (13.632 g, 100 mmol) was dissolved in 100 ml of diethyl ether and 
kept at 0 °C while a solution of pyridine (8.226 g, 104 mmol) in 75 ml of ether was ad-
ded dropwise with stirring. The precipitate was filtered, washed with 100 ml of ether 
and dried in vacuum until constant weight. Resulting white solid was dissolved in DMF 
to obtain 1M solution and stored in dry place. Yield 14.814 g (68.8 %) 1H NMR: 8.56 
(2H, m, -N-CH-CH-CH-); 7.97 (1H, m, -N-CH-CH-CH-); 7.54 (2H, m, -N-CH-CH-
CH-).
N-(2,2-bis(hydroxy(methoxy)phosphoryl)ethyl) β-alanine (101)
Beta-alanine  acid  (0.055  g,  0.617  mmol)  was  dissolved  in  4  ml  of  pyridinium di-
chlorozincate DMF solution (1M) at 70°C.  Then 1 ml of tetramethyl ethenylidene-1,1-
bisphosphonate (2, 0.150 g, 0.614 mmol) DMF solution was added. Reaction mixture 
was stirred at 70°C for 72 hours. DMF was removed in vacuum and the residue was dis-
solved in 5 ml of warm water and 5 ml of methanol was added. Precipitate was collec-
ted and dried in vacuum until constant weight. Crystallization was repeated two more 
times.  Resulting pale yellow solid was dried in vacuum. Yield 0.034 g (18.1 %) 1H 
NMR:  3.7  (d,  6H,  d,  3JHP=10.83,  OCH3);  3.5  (2H,  td,  3JHP=14.70,   3JHH=6.89,  -P-
CH(CH2)-P-); 3.4 (2H, t,  3JHH=6.0, -CH2-CO2H); 2.9 (2H, t,  3JHH=6.1, -CH2-NH-); 2.7 
(1H, tt,  2JHP=21.6,  3JHH=13.6, -P-CH(CH2)-P-).  31P NMR: 19.0 (s).  13C NMR: 174.6 (s, 
CO2H); 52.7 (d, 2JCP=5.78, OCH3); 45.4 (t,  2JCP =3, CHCH2); 43.8 (s, NHCH2); 34.0 (t, 
1JCP=122, -P-CH-P-); 30.3 (s, CH2CO2H).
N-(2,2-bis(hydroxy(methoxy)phosphoryl)ethyl)  γ-aminobutyric acid (102)  Gamma-
aminobutyric  acid  (0.063 g,  0.615 mmol)  was  dissolved  in  4  ml  of  pyridinium di-
chlorozincate DMF solution (1M) at 70°C.  Then 1 ml of tetramethyl ethenylidene-1,1-
bisphosphonate (2, 0.150 g, 0.614 mmol) DMF solution was added. Reaction mixture 
was stirred at 70°C for 72 hours. DMF was removed in vacuum and the residue was dis-
solved in 5 ml of warm water and 5 ml of methanol was added. Precipitate was collec-
ted and dried in vacuum. Crystallization was repeated two more times. Resulting pale 
yellow hygroscopic solid  was dried in  vacuum until  constant  weight. Yield  0.027  g 
(12.5 %) 1H NMR 3.7 (6H, d,  3JHP=10.8, OCH3); 3.5 (2H, td,  3JHH=7.0,  3JHP=15.1,  -P-
CH(CH2)-P-); 3.0 (2H, m, -CH2-CO2H); 2.8 (1H, tt,  2JHP=22.5,  3JHH=7.0, -P-CH(CH2)-
P-); 2.5 (2H, t, 3JHH=7.0, -CH2-NH);  2.0 (2H, quint, 3JHH=7.0, -CH2-). 31P NMR 19.5. (br. 
s).  
N-(2,2-bis(hydroxy(methoxy)phosphoryl)ethyl) 6-aminocaproic acid (103)
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6-Aminocaproic acid (0.081 g, 0.615 mmol) was dissolved in 4 ml of pyridinium di-
chlorozincate DMF solution (1M) at 70°C.  Then 1 ml of tetramethyl ethenylidene-1,1-
bisphosphonate (2, 0.150 g, 0.614 mmol) DMF solution was added. Reaction mixture 
was stirred at 70°C for 72 hours. DMF was removed in vacuum and the residue was dis-
solved in 5 ml of warm water and 5 ml of methanol was added. Precipitate was collec-
ted and dried in vacuum. Crystallization was repeated two more times. Resulting white 
hygroscopic solid was dried in vacuum until constant weight. Yield 0.053 g (18.4 %, 
purity  est.  90  %)  1H  NMR  3,7  (6H,  d,  3JHP=10.7,  OCH3);   3.5  (2H,  td,  3JHH=7.0, 
3JHP=14.5, -P-CH(CH2)-P-); 3.1 (2H, m, -CH2-CO2H); 2.8 (1H, tt,  2JHP=22.2,  3JHH=7.0, 
-P-CH(CH2)-P-); 2.4 (2H, m, -CH2-NH); 1.8 (2H, m, -CH2-CH2-CH2-CH2-CO2H); 1.7 
(2H, m, -CH2-CH2-CH2-CH2-CO2H); 1.4 (2H, m, -CH2-CH2-CH2-CH2-CO2H). 31P NMR 
19.5 (br. s).
N-(2,2-bis(hydroxy(methoxy)phosphoryl)ethyl)  L-lysine  (104)          
L-lysine (0.090 g, 0.615 mmol) was dissolved in 4 ml of pyridinium dichlorozincate 
DMF solution (1M) at 70°C.  Then 1 ml of tetramethyl ethenylidene-1,1-bisphosphon-
ate (2, 0.150 g, 0.614 mmol) DMF solution was added. Reaction mixture was stirred at 
70°C for 72 hours. DMF was removed in vacuum and the residue was dissolved in 5 ml 
of warm water and 5 ml of methanol was added. Precipitate was collected and dried in 
vacuum. Crystallization was repeated two more times. Resulting white hygroscopic sol-
id was dried in vacuum until constant weight. Yield 0.032 g (11.6 %, purity est. ≤80 %) 
1H NMR 1.6  (2H,  m,  -CH2-CH2-CH2-CH2-CO2H);  1.8  (2H,  m,  -CH2-CH2-CH2-CH2-
CO2H);  2.0  (2H,  m,  -CH2-CH2-CH2-CH2-CO2H);  2.8  (1H,  dist.  tt,  2JHP=21.5,  -P-
CH(CH2)-P-); 3.0 (2H, m, -CH2-NH); 3.2 (1H, m, -CH(NH2)-CO2H); 3.5 (2H, m, -P-
CH(CH2)-P-); 3,7 (6H, d, 3JHP=10.2, OCH3). 31P NMR 19.5 (br. s).
2.2. RESULTS AND DISCUSSION
2.2.1. SYNTHESIS PLANNING 
The target structural features suggest that the reasonable strategy of synthesis  
utilize a ready P–C–P scaffold. It narrows the choice of synthetic methods to carb -
anion method or Michael addition (Scheme 24) that are based on tetraalkyl methyl -
ene-1,1-bisphosphonic acid (98) as a starting material.
Figure 7
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To assess these synthetic paths a preliminary set of experiments has been per -
formed. Following the first method a 3-bromo-propionic acid ester was expected to 
react with  tetramethyl methylene-1,1-bisphosphonic acid (98) in presence of sodi-
um hydride in dry THF. This reaction have proved to be reliable if strong metal hy -
drides and very dry media are used128,127.  Unfortunately the repeated experiments 
with the sodium hydride have not led to expected products of conjugation. The de -
velopment of this synthesis might give desired compounds, but the optimal condi -
tions then might present a practical challenge.
The evaluation of Michael addition method was done in experiments with tet-
ramethyl ethenylidene-1,1-bisphosphonic acid (TMEBP, 99) and tert-butyl glycine 
hydrochloride  in  methanol.  As  a  result  a  conjugate  was  observed  by  1H  NMR 
(though it was not isolated) and this have shown a potential of method for optimiz -
ation. 
A priori  the  nucleophilic  addition  of  ethenylidene-1,1-bisphosphonate  and 
amino group is driven by electron deficiency on terminal carbon of double bond 
and by nucleophilicity of  amino-reagent  (Scheme 25).  Typically the polar  protic 
solvents are used to dissolve amino acids due to their limited scope of solubility  
especially in their free state. This, in turn leads to a high degree of protonation of  
amino acid N-terminus and its shift to non-reactive state. Moreover omega-amino 
acids can theoretically exist in acyclic zwitterionic or in intramolecular hydrogen 
bonded state which also can contribute to reduction of their reactivity as N-nucleo-
philes (Scheme 26). 
Scheme 24. 
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The general base catalysis appears to be suitable to maintain a neutral state of  
N-terminus of amino acid, but the P–C–P bonds are labile at pH values higher than  
12137 and the use of tertiary or secondary amines with tetramethyl methylene-1,1-
bisphosphonic acid (1) necessarily implies bisphosphonate partial deprotection 137. 
These  considerations  led  to  the  search  of  aprotic  reaction  medium  for  free 
aminoacids. In literature data such media are suggested by Ryadnov  et al.140 and 
consists of DMF solution of pyridinium complexes of Lewis acids . Although the 
precise mode of amino acid solvation in such media is not known i.e. whether dis -
solved amino acid  is  in  zwitterion  form (Scheme 27)  or  not,  so far  that  is  only 
way141 to perform reactions of free amino acids in aprotic polar solvents. 
An additional complexity to the synthesis is gained by necessity of symmetrical 
deprotection of  bisphosphonate on one of synthesis  stages.  This  can be done by 
one  of  the  methods  described in  section  1.7.3.  An inorganic  salt  was  applied  to 
TMEBP (2)  with  formation  of  dimethyl  ethenylidene-1,1-bisphosphonate  sodium 
Scheme 25
Scheme 27Scheme 26
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salt  (DMEBP,  3)  as a pale-brown solid.  DMEBP can be used as an intermediate 
product of synthesis and in the present study it was used for a test reactions. 
The  first  trial  of  the  reaction  in  DMF:pyridinium dichlorozincate  solution 
have shown: (a) the reaction proceeds upon heating within a period of three days,  
(b) the product bisphosphonate has ionic nature – hygroscopic, dissolves easily in  
water  and  precipitates  after  addition  of  acetone,  methanol  or  ethanol,  (c)  the 
product bisphosphonate is a conjugate of target structure. The products were isol -
ated with iterative precipitation in water – water:methanol system with moderate  
yields. 
2.2.2. DEVELOPING THE REACTION 
The reaction of tetramethyl ethenylidene-1,1-bisphosphonate with four amino 
acids in DMF:pyridinium dichlorozincate  medium led to a target compounds with 
moderate yields. The observation of the process at moderate heating (60-70°C)  by 
1H NMR has shown that the reasonable degree of conversion is achieved after 72 
hours. 
In order to find an optimal temperature mode a reaction mixture (Scheme 28,  
n=1) was observed at five temperature points by 1H and 31P NMR the latter being 
characteristic. In a simple approach it has been shown that a starting material un -
dergoes a transformation at 60-70°C within one hour (Figure 7). It is a matter of 
discussion what kind of transformation takes place during this rapid change. The 
fact that a significant conversion of TMEBP into conjugate product (3a-3d)  was 
observed only after several hours at 70°C (the rest conditions being the same) lead  
to  assumption  that  the  nucleophilic  attack  of  amino  acid  is  a  rate-limiting  step 
while  previous  steps  are  fast.  On  the  other  hand  a  clear  difference  of  chemical  
shifts of DMEBP and intermediate and singlet signal of latter mean that a chemical  
Scheme 28
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environment of both phosphorus atoms is changed during this rapid transformation.  
This  suggests  a   deprotection  step  and  formation  of  intermediate   partial  ester 
pyridinium salt to be the first step of the reaction. However this hypothesis is to be  
evaluated, for instance via synthesis of proposed intermediate in control test.
In  proposed  mechanism  a  pyridinium  complex  is  responsible  for  methyl 
cleavage and N-methyl  pyridinium cation is formed. During a methyl  cleavage a 
negatively charged zinc chloride is donating an electron to the deprotected oxygen 
acting  as  a  promoting  agent.  If  such a  step  takes  place  then  an  isolation  of  N-
methyl pyridinium salts (A, B, Scheme 29) might be possible. Once the intermedi-
ate diester (B) is formed a slow stage of nucleophile addition is following. The ad-
duct (C)  is  probably losing pyridinium cations during the isolation since corres-
ponding 1H NMR signals are observed in crude product, but strongly decay when 
the purification is done.
The control reactions of free amino acids with TMEBP are impossible due to 
insolubility of former in DMF. The control reactions were set with O-methyl amino 
acids  hydrobromides  in  presence  of   equimolar  diisopropylethylamine  in  DMF 
with and without pyridinium dichlorozincate. Opposite to expected in these reac -
tions  conjugate  structures  were not  observed.  That  was probably due to  a  lower  
rate of reaction or effects of the media that might have complex acid-base equilib -
ria.
Figure 9. 31P NMR. From the top to the bottom: 20°, 35°, 50°, 60°, 70°C after 1 hour 
each. The bottom spectrum is a DMEBP reference.
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An additional series of reactions was set to extend the synthesis to more com-
mon methanol and water. Protected amino acids (109-111) were tested for their re-
activity with TMEBP (99) and DMEBP (100) in methanol, while free amino acids 
(105-108) were tested with these bisphosphonates in water. The reaction of TME-
BP with methyl  β-alanine in methanol and free  β-alanine in water produced some 
product  of  double  bond  conjugations  as  observed  by  1H  NMR,  but  these  com-
pounds were not isolated. In contrast to tetraester (99) the DMEBP (100) have pro-
duced  a  conjugate  (observed  in  the  same way)  only with  a  methyl  β-alanine  in 
methanol.
Scheme 29. A suggested mechanism of reaction
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2.2.3. PURIFICATION TECHNIQUES 
The method applied for a crude isolation of amino acid conjugated DMEBP 
was based on manipulation of the solvatation capability of the water solution. As  
the procedure was iteratively repeated the purity of the compounds was increasing.  
However the target product might be soluble to some extent in methanol-water sys -
tems as well as  some impurities might have the same properties in these solution 
thus the method is suffering from both selectivity and target compound losses. This  
in turn distort the yield comparison and quantitation and restrict the development  
of the reaction based on subtle differences.
The  chromatography  is  the  basic  method  routinely  used  for  separation  of 
complex mixtures of compounds in laboratory practice. In need for reliable prepar -
ation  and  analysis  tools  for  bisphosphonate  drugs  several  methods  were  de -
veloped142.  Thin-layer  chromatography  was  used  for  monitoring  chemical  reac-
tions. In all experiments a normal phase stationary phase - silica and neutral alu -
mina  -  was  strongly retaining  a  bisphosphonate  (detected  in  366 nm UV irradi -
ation) and the rest of components could be observed in elution line. The apparent  
strength  of  polar  interactions  with  stationary  phase  in  case  of  protected  amino 
acids and their possible products was as strong and the interaction is attributed to  
the amino group of the components. Possible solution for silica based chromato-
graphy can be use of functionally modified silica 143 and/or a “reversed” stationary 
phase144.  
The ion exchange method of separation is typical for bisphosphonates owing 
to their strong anionic character145,146. This approach is applicable to the obtained 
bisphosphonate diesters bearing two additional ionic centers – a carboxylic and a 
secondary amino groups. Consequently a cation and anion exchange can take place  
for these compounds. Additionally the cation exchange can be used to liberate am-
monium cation that might exist in the product bisphosphonate for a selective puri -
fication. The anion-exchange should utilize the differences in acidity of phosphon -
ic and carboxylic components when phosphorous species preserve anionic form at  
lower  pH values.  This  idea  was  tested  in  a  single  experiment  with  strong  base 
Dowex 1x8 resin in a batch method with a set of HCl:KCl buffers. The buffer pH 
was discretely varying from 6 to 1,5 units and final sample was extracted with 1M 
hydrochloric acid. Unfortunately the samples had a strong concentrations of inor-
ganic components of buffer and reliable observations could not be made. The test  
of  cation  exchange was done with  strong acid   Amberlyst  15 resin  in  a  column 
method with pre-treatment of the column by NaOH, but the bisphosphonate was re -
tained by the resin probably because of amino group interactions. Another reason 
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might be a degradation of bisphosphonate in strong basic environment of resin. As 
a result it can be concluded that ion exchange interactions take place, however for  
the practically relevant performance the type of resin and the method should be op -
timized.
2.2.4. FURTHER RESEARCH PROBLEMS 
During the study a synthetic path to P,P'-dimethyl ethenylidene-1,1-bisphos -
phonic acid and ω-amino acids conjugates was found. The study has revealed sev-
eral problems related to the synthesis of bisphosphonate-amino acid conjugate P,P'- 
diesters, which solution will certainly improve presented synthetic path. 
 The current yields show that the reaction conditions are sub-optimal and the  
conversion degree is low. Elucidation of role of the pyridine complex reagent and 
the  solvent  in  the  reaction  mechanism will  provide  a  stronger  rational  basis  of  
search. The conjugation of protected and free amino acids with TMEBP and DME-
BP might be observed in water and methanol if general base catalysis is tested for  
applicability.
The problem of reproducible yielding of zwitterionic bisphosphonate conjug-
ates present a challenge in practical field. The reversed phase chromatography will  
probably suffer from lack of retention of bisphosphonate products.  Ion exchange 
methods along with studies of acidity constants (e. g. by 1H, 13C and 31P NMR ob-
served titration) can provide a good selectivity based on properties of individual  
conjugate.
Besides problems mentioned above the compounds synthesised require an as-
sessment in one of proposed applications – as an imaging agent or transport moiety 
or in co-transport with other transport units. 
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